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The Islet Amyloid Polypeptide hormone Amylin:
 Its function, effects and uses in medicine
11.05.12
 Amylin is a 37-residue β-cell pancreatic peptide hormone co-secreted in parallel with 
insulin in response to eating (Kraemer et al., 2011; Vella et al., 2002). Because of amylin’s 
function in diabetes and obesity, members of the healthcare field such as doctors, nurses and 
registered dietitians who work with these common conditions would benefit from understanding 
the hormone’s endogenous effects and its use as a medication. Though amylin was discovered 
much later than insulin, research on the peptide hormone has exploded in the last decade, as 
evidenced by the quantity of contemporary papers published on the subject. The more research is 
done, the more is discovered about amylin’s numerous roles in metabolism and pathology. 
Amylin has several different names. It is otherwise known as Islet Amyloid Polypeptide hormone 
(IAPP). Though the term is interchangeable, IAPP is usually used in European research while 
amylin is preferred in American work. Pramlintide is the name given to the synthetic version of 
amylin. It has the the same functions and thus is equivalent to the endogenous hormone. This 
paper will discuss amylin as a glucoregulator in the postprandial period, its effects on adiposity, 
energy metabolism, its role in contributing to pathology, as well as clinical use of its synthetic 
analogue to help manage diabetes mellitus and obesity.
Glucoregulation
 Studies have found that amylin affects glucoregulation in the postrprandial period by 
several mechanisms which, in conjunction, have a significant benefit on glycemic control. These 




  Slower rates of gastric emptying affect the postprandial (after a meal) rise in blood 
glucose for the simple reason that sugars enter the bloodstream more slowly. Slower absorption 
into the body means that blood glucose (BG) levels will have smaller incremental areas under the 
concentration curve when graphing changes in BG over time (Chase, Lutz, Peneck, Zhang, & 
Porter, 2009). In other words, blood sugars will not peak as high when gastric emptying rates are 
slowed.  A study done in 2002 by Vella et al. looked into the mechanism of pramlintide in 
diabetics. Type 1 and 2 diabetics participated because both have low or non-existent levels of 
endogenous amylin (in advanced states of type 2 DM). Participants were randomly assigned to 
be given either of two different doses of pramlintide or a placebo before eating meals containing 
isotopic carbon 13C. As the isotopic meal is metabolized, exhaled CO2 begins to contain 13C. 
Isotopic exhaled CO2 correlates to the digestive state of the food, and this was measured in the 
study. 
 Results showed a significant, though not dose-dependent, delay of gastric emptying in 
participants given pramlintide. This effect was shown to be equal in type 1 and 2 diabetics. A 
relationship between the rate of gastric emptying and plasma concentrations of pancreatic 
hormones was also demonstrated. This study found that patients given pramlintide had slower 
gastric motility which correlated with lower pancreatic hormone concentrations in the blood. 
 These findings are important to elucidating the physiological mechanisms by which 
amylin cause changes in the body. These mechanisms are complex and not yet well understood, 
however two explanations are suggested. The first is an effect on the stomach by gut hormones 
and the second by central neural control (Lutz, 2011; Turek et al., 2010; Vella et al., 2002). 
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Because the stomach has no receptors for amylin, hormonal control may be exhibited by 
affecting the actions of other hormones known to inhibit gastric rate such as cholecystokinin 
(CCK), leptin and incretins GLP-1 and GIP36. The second likely scenario is amylin acting on the 
central nervous system, a hypothesis supported by several animal studies cited by Vella and 
coworkers (2002). Rats have been shown to have amylin receptors in an area of their brain which 
controls the vagus nerve, which in turn controls the pancreas and stomach. In further support of 
this hypothesis, the effects of amylin cease when the vagus nerve was cut in study animals. It is 
important to also consider the possibility that amylin may cause physiologic changes through 
both hormonal and central nervous mechanisms simultaneously.
Glucagon Secretion
 Research suggests that amylin’s effect on gastric emptying alone can alter postprandial 
glucose response. However this is only one of IAPP’s actions, as the hormone has been shown to 
also decrease postprandial glucagon secretion. 
 It is first important to understand glucagon’s role in the body. Glucagon is another 
pancreatic peptide hormone which functions essentially opposite of insulin. It signals the liver to 
engage in gluconeogenesis and gluconeolysis, typically during times of hypoglycemia to raise 
blood glucose. Diabetics however, lack the ability to suppress glucagon secretion during 
hyperglycemic postprandial periods. Meier, Kjems, Veldhuis, Lefebvre, & Butler’s study from 
2006 indicates that the inappropriate glucagon secretion typical of diabetes is due to a lack of 
insulin, but the 2009 study from Chase et al. tells us that exogenous insulin does not have the 
same inhibitory effect as endogenous insulin on pancreatic alpha cell’s secretion of glucagon. 
This means that insulin-treated diabetics will continue inappropriate glucagon secretion into the 
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postprandial period despite administration of mealtime insulin and will struggle with managing 
blood glucose. The study from Chase and others found that pramlintide suppresses glucagon 
after a meal while treatment with exogenous insulin does not. In support of this finding, one 
clinical investigation gave type 1 diabetics a meal with a known amount of carbohydrate and 
injected the control group with their normal insulin bolus while the experimental group received 
insulin plus a dose of pramlintide (Heptulla, Rodriguez, Bomgaars, & Haymond, 2005). 
Participant’s blood concentrations of glucose, glucagon and IAPP/pramlintide were monitored 
for seven hours afterward. Findings from this trial indicated that pramlintide significantly 
lowered blood glucose excursions and reduced glucagon concentrations. These results point to 
IAPP’s significance as a glucoregulator by preventing untimely secretion of glucagon, thus 
preventing or reducing hyperglycemic postprandial events. 
Adiposity 
 In addition to the glycemic control that amylin has been shown to exert, it is believed to 
be a signal for adiposity; the amount of fat in the body. Experimental evidence indicates a 
relationship between obesity and amylin, and shows amylin’s similarities to other known 
adiposity signals. Furthermore, amylin’s role in satiation contributes to reduced adiposity. 
 Several discoveries point to a positive relationship between IAPP levels and obesity as 
evidence for amylin as an adiposity signal (Lutz, 2012; Turek et al., 2010, Woods, 2004). First, 
plasma amylin concentrations have been shown to be higher in obese rats, and secondly, rats 
which are fed to become obese also showed higher levels. Lastly, these results were confirmed in 
obese humans who had significantly higher amylin levels when fasting and postprandial than 
their thinner peers (Enoki et al., 1992).
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 More than a correlational relationship, hormonal and genetic interventional experiments 
show causal relationships between amylin and obesity (Lutz, 2011; Lutz, 2012; Weilinga et al., 
2010). Rats who were administered amylin decreased body weight specifically in fat mass. 
Moreover, when the effects of amylin’s adiposity were blocked with an amylin agonist, the mice 
receiving the agonist medication gained significant fat mass. This finding tells us that without 
amylin’s mediation, adiposity increases. This implies that endogenous plasma amylin found in 
obese specimens is higher because amylin is not working as effectively (likely due to 
insensitivity) and thus is overproduced.  Further tests investigated whether IAPP’s action was 
substantial in duration. Rats were put into three groups and either overfed, fed normally or 
underfed, and half from each group were given amylin. Regardless of their previous nutritive 
states, at the end of two weeks, all amylin-infused rats had lower body weights than their 
counterparts. This suggests that amylin levels in the blood may set homeostatic weight controls 
to a lower mass and contribute to weight constancy.
 Genetically-induced changes in endogenous amylin levels also provide similar evidence. 
In 2010, Turek and others created mice whose amylin-encoding gene was knocked out. They 
found that these deficient mice were heavier than wild-types. This same study also concluded 
that the body’s response to leptin, another known and well-studied adiposity signal, is modulated 
by amylin and synergistically leads to weight loss.
Satiation
 IAPP’s action in satiation is intricately related to adiposity (Woods, 2005). Regulating 
nutrient intake by satiation alters carbohydrate consumption, so satiation is also related to 
glucoregulation. With that said, satiation is a complicated cascade of signals, so much so that the 
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gut is often referred to as the second brain. As much of the subject matter is beyond the scope of 
this paper, (and partly still beyond the understanding of modern science) the information 
presented here is general. Research indicates that amylin reduces eating over a sustained period 
by acting in the brain on the area postrema, a structure in the medulla oblongata that controls 
feeding. 
 Amylin is seen to work like a known satiation signal CCK, a gastrointestinal peptide 
hormone which has many physiological effects including influences similar to amylin’s 
mediation of gastric emptying and satiation (Woods, 2004). Amylin administration, unlike CCK, 
appears to cause sustained reductions in food intake and body weight without compensatory 
behavior such as increased meal frequency (Lutz, 2011). Animal studies have shown that one 
injection of IAPP can reduce eating for up to 24 hours. What’s more, after that initial reduction 
of 24 hours, animals did not “make up” for the deficiency in following days. This data is 
suggestive of amylin’s ability to cause weight loss and to prevent re-gaining it. In another 
experiment, rats were centrally administered amylin (i3v infusion: a direct injection in the third 
ventricle of the brain) and monitored for meal size and frequency. Results were similar to 
peripheral IV infused amylin, demonstrating significant weight loss, reduced meal sizes and in 
higher doses, less frequent meals.
 Lutz adds in his 2012 article that amylin lowers food intake in rodents without causing a 
conditioned taste aversion. This was tested by giving rats amylin and recording their preferences 
between water and sugar-water solutions. There were no changes found in preferences after 
amylin administration, though a large total reduction in eating was noted. A control substance 
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known to cause taste aversion was separately administered and did trigger a significant change in 
preferences. 
 The question of how amylin produces satiation is not well answered. It has not yet been 
discovered whether amylin’s signals for adiposity and acute satiation are separately processed in 
the brain (Lutz, 2011; Lutz, 2012). Ongoing research is looking into the neural pathways by 
which amylin creates the sensation of satiation. So far, it is suspected that at least part of the 
pathway is through the release of dopaminergic catecholamines.
 Though much of the research presented in this section concerning adiposity has been 
done on rodents, it is not unreasonable to assume that the results also apply to humans, but 
perhaps the magnitude of effects vary between species (Enoki et al., 1992; Lutz, 2012). More 
research on pramlintide use in humans will come later in this paper. Nevertheless, a number of 
studies have shown that high levels of amylin correlate with obesity and insensitivity is 
suspected to have a causal relationship with obesity. Furthermore, amylin plays a part in the 
satiation cascade, secondarily affecting adiposity and glucoregulation by limiting nutrient intake. 
Energy Metabolism
 A study Lutz  published in 2011 suggests that the weight-reducing action of IAPP may be 
due to an effect on energy expenditure in addition to reducing energy intake by satiation. This 
paper reviews a number of studies done on rodents where the effect of amylin on energy 
expenditure was clearly demonstrated. Rodents were pair-fed so energy intakes were the same 
while only one was given amylin. The amylin-dosed rodent had a significantly lower body 
weight and adiposity at the end of these studies. IAPP appears to either increase total energy 
expenditure or prevent the body’s natural decrease in energy expenditure when calorie intake is 
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restricted. These effects are thought to perhaps increase the proportion of metabolically active 
lean body mass or by increasing fat oxidation, though experiments have not had consistent 
results. 
Pathology
 The information presented thus far explains metabolic actions of endogenous IAPP as it 
is intended to work. Scientists have discovered however, that amylin also has significant 
pathologic effects when it starts to work in ways it was not meant (Aitken, Loomes, 
Konarkowska, & Cooper, 2003; Mandrup-Poulsen, 2001; P. Westermark, Engstrom, Johnson, G. 
Westermark, & Betsholtz, 1990). In the bodies of persons affected by this pathology, misfolded 
molecules of IAPP aggregate into insoluble fibril structures that can become quite large. These 
aggregations of amylin are called amyloid. Amyloid causes cystic pockets in the tissues where 
they occur and it is believed that this may lead to the beta cell dysfunction that causes diabetes. 
In fact, the most characteristic morphological alteration, seen in up to 95% of type 2 diabetics, is 
the extracellular deposition of amyloid. Interestingly, much research is also being done on 
amyloid-forming proteins elsewhere in the body, namely in the brain, and it is suspected that this 
same amyloid mechanism is responsible for the occurrence of Alzheimer’s disease and 
Parkinson’s (Baine et al., 2009; Fandrich, 2012). Recent research in this area concentrates on 
three things: the mechanisms of aggregation, toxicity, and ways to prevent, reduce or dissolve 
amyloid. 
Mechanism of Aggregation
 In order to stop IAPP from aggregating, scientists must first understand how the protein 
comes together in the first place. A study in 1990 by Westermark et. al. noted that only a limited 
9
number of species are prone to amylin amyloidogenesis. Their study investigated how the amino 
acid sequence in amylin varied across species. Westermark’s team synthesized IAPP and 
substituted amino acids one by one and in groups, and then observed their tendencies to 
aggregate. By this process of elimination, they found that residues in positions 20-29 were 
primarily responsible for aggregate action. Further studies have found a secondary 
amyloidogenic region at residues 13 and 15-17 (Fox et al., 2010). Other analysis adds to this, 
indicating that assembly is due to hydrophobic interactions and the formation of hydrogen bonds 
(Cheon et al., 2007; Fandrich, 2012). Using computer models, Cheon and coworkers revealed 
that oligomeric assembly occurs in two steps. First, assembly is characterized by hydrophobic 
interactions to sequester hydrophobic residues away from the solvent, resulting in the formation 
of elastic oligomer groups. In the second step, interchain hydrogen bonding drives 
reorganization, and can expose hydrophobic residues. This hydrophobic exposure is important, 
because it can explain amyloid toxicity to membranes and therefore dysfunction of the protein 
and its cell. 
Toxicity
 As previously mentioned, amyloid-filled cystic pockets may lead to β-cell dysfunction 
(Mandrup-Poulsen, 2001), but we have not yet seen how amyloid exerts its toxicity. Amyloid 
takes different forms as the aggregations grow, and these have different effects. Scientists are still 
debating which forms are responsible for cell death. 
 First is the amyloid hypothesis; the mature aggregated fibrils of amyloid proteins, cause 
cell death. Mature amyloid fibrils are fairly rigid and large. This may cause physical impairments 
in the tissues, activate inflammatory responses or overload protein degradation machinery. 
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 The second and more conventional oligomeric hypothesis posits that smaller, thinner 
aggregations in oligomeric intermediate stages cause toxicity (Eliezer, 2006; Fandrich, 2012; 
Sokolov, et al., 2006). Mechanisms of oligomer-mediated toxicity can be similar to mature 
fibrils, except for the physical impairment of tissues unique to fibrils. Unique to oligomers on the 
other hand, is their clearly observed activity in increasing membrane permeability. Amyloid 
intermediates are thought to form ion channels or affect the integrity of cellular lipid bilayers, 
breaking the barrier separating the intracellular and extracellular spaces. This increase in ion 
permeability disrupts homeostasis and leads to cell death. Though oligomers bare similarity to 
other known toxins that form pores in cell membranes, electrophysiology experimentation from 
Sokolov and others (2006) favors membrane integrity disruption. Their work displayed increases 
of membrane permeability without any evidence of ion channel formation. More research 
concerning the mechanisms of toxicity is important because a better understanding may help 
target therapeutic development to prevent membrane permeabilization and thus prevent cell 
death. 
Inhibition or Dissolution of Amyloid Aggregations
  IAPP is the most amyloidogenic protein known and research on how to stop or reverse 
IAPP aggregations has been intensive. A number of compounds have been shown to reduce or 
eliminate aggregation in vitro (Aitken et al., 2003). Aitken et al. investigated the ability of 
several polycyclic compounds, including the common antibiotic tetracycline, to interfere with the 
conversion of synthetic human amylin into its insoluble amyloid form. Remarkable inhibition 
was seen with several of these compounds at a 1:1 molar ratio with amylin. Tetracycline was 
shown to still hinder conglomeration too, though to less effect compared to other compounds. 
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Other chemicals such as resveratrol, found in red wine, and dyes like Congo red have been 
investigated for effective inhibition properties (Evers et al., 2009; Watson, Lander, & Selkoe, 
1997). More research is targeted at developing compounds that specifically interact with the 
protein regions responsible for aggregation through hydrophobic interactions and hydrogen 
bonding (Amijee, Madine, Middleton, & Doig, 2009). These compounds compete for 
aggregation regions with other molecules of amylin, ultimately preventing conglomeration. 
 We have seen that aggregations cause damage by physical impairment and membrane 
disruption (Mandrup-Poulsen, 2001). Though some compounds being researched offer the 
promise of preventing aggregations and thus the diseases that occur because of them, they are not  
yet practical as interventions. To reach high enough concentrations to work would require 
ingesting large amounts of the chemical and this would have side-effects. Additionally, there are 
many challenges in directing these compounds to the parts of the body where they need to be. 
The search for other chemicals with anti-aggregation properties at lower concentrations 
continues. 
Clinical Use
 Because of the pharmacodynamics that amylin has displayed in glucoregulation, 
adiposity and energy metabolism, the use of its synthetic analogue pramlintide in the 
management of diabetes and weight loss were indicated after safety of its administration was 
verified in clinical trials. It is also essential to discuss the role of nutrition in disease 
management, and how the addition of pramlintide can support efforts.  
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Diabetes
 Clinical trials have evaluated the administration of pramlintide to help control diabetes 
and found it to be effective (Chartrand, 1997; Lush, Darsow, Zhang, Lorenzi, & Frias, 2007; 
Younk, Mikeladze, & Davis, 2011). Pramlintide was first tested for its ability to improve 
glycemic control, and found that over the long-term, patients given the drug had sustained 
reductions in average HbA1c scores indicating improved glycemic control with fewer episodes 
of hyperglycemia. Adding pramlintide to a treatment regimen also reduced the amount of basal 
insulin patients required, and caused no weight gain (unlike treatment with exogenous insulin). 
These results make pramlintide a possible alternate to the addition of mealtime insulin if 
treatment intensity needs to be increased in order to control BG.
Weight Loss
 After considering results from animal studies, clinical trials were conducted with humans 
to test pramlintide’s use as a tool for weight loss (Lutz, 2012). Results were promising, especially 
when pramlintide was combined with metreleptin, leptin’s synthetic analogue (Ravussin et al., 
2009). Single hormone treatments were effective, but combination therapy worked to decrease 
body weight an average of 12% in five months with more potential loss projected. It is suspected 
that a maintenance dose would need to be continued to sustain weight loss.
Safety
 Considering that amylin has been shown to have pathological effects, one may wonder if 
giving people the hormone would be safe. In fact, the synthetic version has been altered to 
prevent aggregation, and its administration had been demonstrated to be well tolerated. 
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 As we saw in the study from Westermark and coworkers, several specific amino acids 
give rise to aggregation (1990). In the synthetic version, these residues are modified or swapped 
out for others so to no longer have amyloidogenic properties, but maintain its pharmacodynamics 
(Heptulla et al., 2005; Vella et al., 2002).
 Other known risks of pramlintide include nausea, vomiting and increased risk of 
hypoglycemic events, especially when combined with another hypoglycemic agent such as 
insulin, most especially acute mealtime insulin (Lush et al., 2007). Careful management of 
dosing is thus required, though some risk is removed by substituting pramlintide for mealtime 
insulin rather than adding it. Nauseous responses to drug administration will generally decline 
after an adjustment period of few weeks. 
Pramlintide & Nutrition
 In the face of pramlintide’s new clinical roles, we must evaluate how this could relate to 
nutritive therapy which is the primary method of managing type 2 diabetes mellitus and obesity. 
In both conditions, pramlintide can be used to supplement nutrition therapy in the case that a 
person cannot reach desired goals with diet alone. With diabetes, the goal is to gain optimal 
glycemic control by limiting spikes, using carbohydrate controlled meal plans and low glycemic 
index foods. The hope of nutritional management is to reduce or prolong the need for additional 
treatment, including pramlintide. A nutritional consultation with a registered dietitian (RD) is 
recommended to ensure that patients have sufficient nutrient intakes for a healthful diet. If 
necessary, nutrient deficiencies may be compensated for with supplements or other dietary 
changes. Considerations for weight loss must also be taken to account. A pramlintide-assisted 
intake-restricted diet has to be monitored closely to ensure that the patients meet macronutrient 
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requirements, such as sufficient complete protein, essential fats, and adequate carbohydrates to 
prevent hypoglycemic episodes. Because RD’s frequently work with diabetics and obese 
patients, it is important for them to be familiar with all treatment options including medications 
to supplement weight loss efforts. Furthermore, an in-depth understanding of the disease process 
and the normal functions of the body are paramount to treat disease. For these reasons, the RD 
and other health professionals should be knowledgable about amylin and pramlintide. 
Conclusion
 In summary, amylin is an important and physiologically active hormone, which helps 
with glucoregulation by delaying gastric emptying and suppressing glucagon release. It also 
appears to raise energy metabolism, and acts as an adiposity and satiation signal. The hormone 
can become pathological when it aggregates, causing tissue damage, and scientists are still 
researching ways to prevent this. Pramlintide has been shown to be useful in clinical settings for 
glycemic regulation in diabetic patients and weight loss. The addition of this medication has 
positive effects on nutritive therapy. The future is promising, as continued research provides a 
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